Alkermes plc (ALKS) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Earnings Reports

• Alkermes (ALKS) Q2 2026: Proprietary Product Sales Jump 34% as Orexin Pipeline Expands
  July 28, 2026
• Alkermes (ALKS) Q1 2026: Proprietary Portfolio Sales Surge 38% as Orexin Pipeline Expands
  May 05, 2026
• Alkermes (ALKS) Q4 2025: Avidel Acquisition Adds $315M Lumerize Upside, Shifts Growth Trajectory
  February 25, 2026
• Alkermes (ALKS) Q3 2025: Proprietary Product Sales Jump 16% as Orexin Pipeline Accelerates
  October 28, 2025
• Alkermes (ALKS) Q2 2025: Proprietary Product Sales Jump 14% as Orexin Pipeline Advances
  July 29, 2025
• Alkermes (ALKS) Q1 2025: Orexin Pipeline Momentum Sets Stage for Dual Data Catalysts in H2
  July 04, 2025
• Alkermes (ALKS) Q3 2024: $200M EBITDA Reset Signals Royalty Cliff, Proprietary Portfolio Now Core Growth Driver
  October 24, 2024
• Alkermes (ALKS) Q2 2024: Proprietary Portfolio Grows 16% as Orexin Pipeline Advances
  July 24, 2024
• Alkermes (ALKS) Q1 2024: Proprietary Portfolio Up 9% as Pipeline and Margin Expansion Take Center Stage
  May 01, 2024
• Alkermes (ALKS) Q4 2023: Proprietary Portfolio Surges 18%, Sharpening Neuroscience Focus
  February 15, 2024
• Alkermes (ALKS) Q4 2023: Proprietary Portfolio Surges 18% as Neuroscience Focus Drives Margin Expansion
  February 15, 2024

Browse all companies